Positive results from immunogenicity testing send Prescient’s shares higher
In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico...
In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico...
In a milestone development regarding its innovative CAR-T cancer therapy programs, Prescient Therapeutics Limited (ASX:PTX) has announced...
Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics...
ASX-listed clinical-stage company Prescient Therapeutics Limited (ASX:PTX) is well-known for developing breakthrough targeted and personalised medicines approaches...
Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug...
With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX: PTX) develops personalised medicines as potential...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel...
On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of...
Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking...
To stay up to date with Prescient Therapeutics news and events, please register your details.